Advances in Neuroimmunology: From Bench to Bedside by Comi C et al.
Editorial
Advances in Neuroimmunology: From Bench to Bedside
Cristoforo Comi,1,2 Umberto Dianzani,2
Filippo Martinelli Boneschi,3 and Daniel L. Menkes4
1 Department of Translational Medicine, Section of Neurology, University of Eastern Piedmont Amedeo Avogadro, 28100 Novara, Italy
2 Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont Amedeo Avogadro, 28100
Novara, Italy
3 Department of Neurorehabilitation and INSPE, San Raffaele Scientific Institute, 20132 Milan, Italy
4Department of Neurology, Oakland University William Beaumont School of Medicine, Royal Oak, MI 48073, USA
Correspondence should be addressed to Cristoforo Comi; cristoforo.comi@med.unipmn.it
Received 5 December 2013; Accepted 5 December 2013; Published 19 January 2014
Copyright © 2014 Cristoforo Comi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The understanding of the interactions between the immune
and the nervous systems and the resultant therapeutic impli-
cations has expanded significantly in the last decade [1].
There have been significant developments in the field of
neuroimmunology as new antibody-mediated disorders have
been described and involvement of the immune system in
the pathogenesis of neurodegenerative diseases has been
established [2, 3]. These discoveries have led to novel and
effective treatments, which have broadened our therapeutic
options regarding neuroimmune disorders [4, 5].
The goal of this special issue was to address the transla-
tional aspects of neuroimmunology, “from bench to bedside,”
in order to update clinicians on basic research discoveries
that will have therapeutic clinical efficacy. Moreover, there
was an emphasis on conditions that have undergone a
systematic nosographic characterization which have resulted
in therapeutic approaches with greater specificity. In this
context, the paper entitled “Immunotherapy of neuromyelitis
optica” provides a framework for understanding an antibody-
mediated central nervous system demyelinating disease that
has a different pathophysiology than multiple sclerosis (MS).
This distinction is important as NMO responds to different
immunomodulating agents than does MS.
The spectrum of pediatric MS has also been the focus of
extensive nosographic revision in recent years, and diagnostic
criteria have been recently revised by the International
Pediatric Multiple Sclerosis Study Group (IPMSSG) [6].
The paper “Pediatric multiple sclerosis: current concepts and
consensus definitions” offers a careful update on risk factors,
clinical manifestations, diagnostic procedures, prognostic
implications, and treatment of this increasingly frequent form
of MS.
MS is a salient neuroimmunological disease for which
the “bench to bedside approach” has provided the greatest
therapeutic advances. Although there aremore treatments for
MS, the study of novel and less explored molecular pathways
ought to provide relevant alternative targets. This concept
is well expressed in the paper entitled “Current understand-
ing on the role of standard- and immuno-proteasomes in
inflammatory/immunological pathways of Multiple Sclerosis,”
in which the authors describe the current knowledge on the
potential role of proteasomes in MS and discuss the pro
et contra of possible therapies for MS targeting proteasome
isoforms.
Immunemediated diseases of the peripheral nervous sys-
tem (PNS) are less studied than their “central” counterparts
[7]. Nonetheless, important advances in both pathogenesis
and treatment of inflammatory demyelinating neuropathies
have been extensively evaluated in the articles authored by
J. B. Weiner and P. Ripellino et al. The first publication
entitled “An update in Guillain-Barre´ Syndrome” provides
a comprehensive discussion of the current state of knowl-
edge on acute inflammatory neuropathies from diagnosis to
treatment. The second article, entitled “Treatment of chronic
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inflammatory demyelinating polyneuropathy: from molecular
bases to practical considerations,” bridges the biological ratio-
nale of immunotherapy to clinical practice also in the context
of pharmacoeconomics.
Finally, the paper entitled “An update in the use of anti-
bodies to treat glioblastoma multiforme” reviews the current
knowledge on an expanding field immunotherapy, which is
expected to have a significant impact on the progression of
these high grade gliomas.
The editors believe that you will agree that this special
issue will prove to be highly valuable to basic scientists and
clinicians alike.
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